Latest News and Press Releases
Want to stay updated on the latest news?
-
Domain Therapeutics announces nomination of best-in-class CCR8 antibody candidate, DT-7012, further strengthening its unique portfolio of GPCR-targeting immunotherapies DT-7012 nominated based on its...
-
Domain Therapeutics announces nomination of first-in-class PAR2 NAM candidate, DT-9045, to unlock new cancer treatment possibilities DT-9045 is a unique drug candidate due to its competitive...
-
Domain Therapeutics presents new data on its EP4R and CCR8 antagonists at 2022 SITC Annual MeetingData unveiled on clinical candidate EP4R antagonist, DT-9081, and CCR8 depleting-antibody...